New technique developed at Washington University in St. Louis uses blood test
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.
Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a groundbreaking, proof-of-concept technique that allows biomarkers from a brain tumor to pass through the tough blood-brain barrier into a patient’s blood using noninvasive focused ultrasound and some tiny bubbles, potentially eliminating the need for a surgical biopsy.
Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and of radiation oncology in the School of Medicine, said while researchers have already learned how to get a drug through the blood-brain barrier into the brain via the bloodstream, no one — until now — has found a way to release tumor-specific biomarkers — in this case, messenger RNA (mRNA)— from the brain into the blood.
“I see a clear path for the clinical translation of this technique,” said Chen, an expert in ultrasound technology. “Blood-based liquid biopsies have been used in other cancers, but not in the brain. Our proposed technique may make it possible to perform a blood test for brain cancer patients.”
The blood test would reveal the amount of mRNA in the blood, which gives physicians specific information about the tumor that can help with diagnosis and treatment options.
Results of the study, which blends imaging, mechanobiology, genomics, immunology, bioinformatics, oncology, radiology and neurosurgery, are published in Scientific Reports April 26, 2018.
Chen; Leuthardt, professor of neurological surgery in the School of Medicine; and researchers from the Schools of Engineering & Applied Science and of Medicine, tested their theory in a mouse model using two different types of the deadly glioblastoma brain tumor. They targeted the tumor using focused ultrasound, a technique that uses ultrasonic energy to target tissue deep in the body without incisions or radiation. Similar to a magnifying glass that can focus sunlight to a tiny point, focused ultrasound concentrates ultrasound energy to a tiny point deep into the brain.
Once they had the target — in this case, the brain tumor — researchers then injected microbubbles that travel through the blood similar to red blood cells. When the microbubbles reached the target, they popped, causing tiny ruptures of the blood-brain barrier that allows the biomarkers from the brain tumor to pass through the barrier and release into the bloodstream. A blood sample can determine the biomarkers in the tumor.
This technique could lead to personalized medicine.
“In many ways this has been a holy grail for brain tumor therapy,” Leuthardt said. “Having the ability to monitor the changing molecular events of the tumor in an ongoing way allows us to not only better diagnose a tumor in the brain, but to follow its response to different types of treatment.”
“Once the blood-brain barrier is open, physicians can deliver drugs to the brain tumor,” Chen said. “Physicians can also collect the blood and detect the expression level of biomarkers in the patient. It enables them to perform molecular characterizations of the brain tumor from a blood draw and guide the choice of treatment for individual patients.”
In addition, Gavin Dunn, MD, assistant professor of neurosurgery, a co-author and leader in cancer immunobiology, plans to use the technique with immunotherapy, which offers precision treatment that targets specific biomarkers in the brain.
“This noninvasive focused ultrasound-enabled liquid biopsy technique can be useful for long-term monitoring of brain cancer treatment response, where repeated surgical tissue biopsies may not be feasible,” Chen said. “Meanwhile, variations within tumors pose a significant challenge to cancer biomarker research. Focused ultrasound can precisely target different locations of the tumor, thereby causing biomarkers to be released in a spatially-localized manner and allow us to better understand the spatial variations of the tumor and develop better treatment.”
The team continues to work to refine the process. The future will require integration with advanced genomic sequencing and bioinformatics to enable even more refined diagnostics. These efforts are being led by co-authors Allegra Petti, assistant professor of medicine, and Xiaowei Wang, associate professor of radiation oncology.
“Our ongoing work is to optimize the technique and evaluate its sensitivity and safety,” Chen said.
Learn more: Noninvasive brain tumor biopsy on the horizon
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Nobel laureates to attend personalized medicine conference in Croatia on February 19, 2019 at 1:00 am
The International Society for Applied Biological Sciences (ISABS), the Mayo Clinic and St. Catherine Hospital have announced the 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo C... […]
- FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib on February 18, 2019 at 10:01 pm
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 19, 2019--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has ac... […]
- The Challenge of Precision Medicine in mCRPC on February 18, 2019 at 6:20 am
Over the past decade, we have used the terms personalized medicine and precision medicine interchangeably. For the most part, patient care has always been personalized. Yes, some want to make it more ... […]
- The Future of Medicine is at the Nanoscale on February 15, 2019 at 1:56 pm
Personalized healthcare is the Holy Grail of medicine—the idea that every illness or disease can be treated on an individual basis for each patient, with medicines, drugs and treatments designed for e... […]
- ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia on February 15, 2019 at 9:24 am
anthropologic genetics and personalized medicine. ISABS Scientific Committee comprises four Nobel Laureates and world's top physicians and scientists. According to U.S. News & World Report, Mayo Clini... […]
- AI and personalized medicine to raise the bar in radiology reporting on February 14, 2019 at 9:10 pm
RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wh... […]
- Microarray Analysis Market - Global Forecast to 2023: Use of Microarrays in Personalized Medicine Present Opportunities on February 14, 2019 at 5:49 am
personalized medicine, genetic disease diagnosis, and various diseases. Asia Pacific is estimated to register the highest CAGR during the study period. In this report, the microarray analysis ... […]
- FDA approved record number of personalized medicines in 2018: report on February 13, 2019 at 12:53 pm
The Personalized Medicine at FDA: A Progress & Outlook Report (PDF) gives credit to the FDA for accelerating the trend of patients and payers embracing personalized medicine. In fact, personalized med... […]
- Biomarker Deals Report on Personalized Medicine and Companion Diagnostics for North America and Europe Region just published on February 12, 2019 at 11:41 pm
Size of the biomarker deals market report with technologies updates, estimate size of various other dependent submarkets. Major players in market were identified through secondary research and their m... […]
via Bing News